Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 12/20 | 0.36 |
| ▸ | BTK | Q06187 | 6/20 | 0.36 |
| ▸ | ITK | Q08881 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15882952 | 0.81 | LRRK2 (0.41) | PRMT5WDR77MAP3K12 | |
| SCHEMBL25299865 | 0.80 | MET (0.34) | METPRMT5WDR77MAP3K12BTK | |
| SCHEMBL7864936 | 0.72 | TNKS (0.43) | ITK | |
| SCHEMBL10269012 | 0.71 | MET (0.43) | METPRMT5WDR77BTKITK | |
| SCHEMBL14384979 | 0.71 | ABL1 (0.31) | — | |
| SCHEMBL29380963 | 0.71 | GSK3A (0.43) | METPRMT5WDR77MAP3K12BTK | |
| SCHEMBL2966812 | 0.71 | GSK3A (0.43) | METPRMT5WDR77MAP3K12BTK | |
| SCHEMBL28664211 | 0.70 | GABRP (0.37) | — | |
| SCHEMBL7921128 | 0.70 | MET (0.46) | METPRMT5WDR77MAP3K12BTK | |
| SCHEMBL31150732 | 0.70 | MET (0.39) | METPRMT5WDR77MAP3K12BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182465-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2024-06-06 | — | — | US | disclosed |
| EP-4303216-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023131122-A1 | FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182465-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, HASPIN | MET 1502/4885PRMT5 4097/4885WDR77 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.